The hire of WS comes as Pall's Leukotrap Affinity Prion Reduction Filter System is evaluated by the UK's National Blood Service and the Irish Blood Transfusion Service.
Results are expected later this year or early in 2006.
Leukotrap removes infectious prions from red cells - the most widely transfused blood component. Prions are associated with causing variant Creutzfeldt-Jakob and other fatal neurodegenerative diseases. A media relations-focused campaign targeted at policy makers is primed at the UK and Ireland but is also likely to take in France, Spain and Portugal.
WS has already worked with Pall, when it promoted news that Leukotrap had been awarded a CE mark, denoting that it meets European safety standards.